Interviews

A new blood test being worked on can detect 8 common cancer types in a way that is less invasive than other tests, said Jeanne Tie, MBChB, FRACP, MD, medical oncologist and associate professor at the Walter+Eliza Hall Institute of Medical Research.

Paul Melmeyer, director of Federal Policy, National Organization for Rare Disorders, discusses factors that have historically been underrepresented in value assessment frameworks for rare disease therapies.

Aledade and Aetna are partnering to bring population health to patients and greater accountability of total cost of care to providers, said Travis Broome, vice president of policy at Aledade.

The biggest clinical challenges that we have in treating multiple sclerosis are 2-fold, explained June Halper, MSN, APN-C, MSCN, FAAN, chief executive officer, Consortium of Multiple Sclerosis Centers.

Thomas Marsland, MD, medical oncologist, discusses his take on the CAR T-cell therapy reimbursement plan put forward by CMS.

Stephen Silberstein, MD, director of the Jefferson Headache Center, discusses patient reactions to being prescribed a CGRP inhibitor.

Joann Sciandra, RN, BSN, CCM, associate vice president of healthcare management, Geisinger Health System, discusses which technologies are having the biggest impact for accountable care organizations (ACOs) in better managing the needs of their patients.

Collaboration between cardiologists and endocrinologists are necessary when caring with patients with diabetes who have had cardiovascular issues in the past, said Jaime A. Davidson, MD, FACP, MACE, professor of medicine, Touchstone Diabetes Center, The University of Texas Southwestern Medical Center.

Is chemotherapy really on its way out? Maybe not, said Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions.

HIV care delivery has always had an ethos in it of really being based on a team-based approach, explained Stella A. Safo, MD, assistant professor of Medicine at the Icahn School of Medicine at Mount Sinai.

Genetic testing and understanding family history of cancer is important because more and more targeted therapies are coming out that are designed to work with specific mutations or inherited forms of mutations, said Sue Friedman, DVM, executive director of FORCE: Facing Our Risk of Cancer Empowered.

There is generally a greater willingness to pay among just about everybody for rare disease therapies, explained Paul Melmeyer, director of Federal Policy, National Organization for Rare Disorders.

The Oncology Care Model (OCM) is pushing cancer centers and cancer programs to make the changes they knew were needed to improve care delivery and patient experiences, said David Ortiz, OCM program director at Montefiore Einstein Center for Cancer Care.

Circulating tumor DNA (ctDNA) can now allow clinicians to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy, said Jeanne Tie, MBChB, FRACP, MD, medical oncologist and associate professor at the Walter+Eliza Hall Institute of Medical Research.

Eric Anderson, MD, PhD, vice chair of neurology, quality at SOC Telemed, discusses the growing field of wearable technology for movement disorders like Parkinson disease.

There has been much speculation about the end of chemotherapy in cancer treatment, but it’s not clear how accurate that is, said Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions.

The person-centered factors that drive outcomes in diabetes requires hospital systems that can actually address those needs, said Kellie Rodriguez, RN, MSN, MBA, CDE, director, Global Diabetes Program, Parkland Health & Hospital System.

Pre-exposure prophylaxis (PrEP) is one of the best interventions we have for preventing and stopping HIV transmission, explained Stella A. Safo, MD, assistant professor of Medicine at the Icahn School of Medicine at Mount Sinai.

Wayne Burton, MD, former global corporate medical director for American Express, discusses what he views as the key takeaways from a migraine peer exchange he recently participated in.

Therapies for rare diseases, such as gene therapy, pose very unique challenges to value assessments in a variety of different ways, explained Paul Melmeyer, director of Federal Policy, National Organization for Rare Disorders.

The long time between when a performance period ends and when the report comes out in the Oncology Care Model (OCM) can make it difficult to measure the impact specific changes are making, said David Ortiz, OCM program director at Montefiore Einstein Center for Cancer Care.

Changes with health plans can be disruptive to patients with diabetes who face changes in supplies and medications that make it difficult to manage their disease, said Jaime A. Davidson, MD, FACP, MACE, professor of medicine, Touchstone Diabetes Center, The University of Texas Southwestern Medical Center.

Things like smoking, poor diet, and lack of exercise can increase a person’s risk of developing cancer, but there are some things that are actually more clinically acute outside of family history that every patient needs to look out for, explained Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.

In the last 2 decades, the cost of healthcare has risen, but the expectations of self-management for people with diabetes has stayed the same, which has made it more challenging to live with the disease, said Kellie Rodriguez, RN, MSN, MBA, CDE, director, Global Diabetes Program, Parkland Health & Hospital System.

From the health system perspective, there needs to be improvement in treating HIV as a comprehensive disease that now goes into aging, explained Stella A. Safo, MD, assistant professor of Medicine at the Icahn School of Medicine at Mount Sinai.

Alliances are going to help community oncology participate in things that, as individual practices, they don‘t have the opportunity to do, said Barry Russo, chief executive officer of The Center for Cancer and Blood Disorders.

Shoshana Lipson, a patient advocate and founder of the “CGRP & Migraine Community ” on Facebook explains the patient perspective of CGRP inhibitors.

With CancerIQ, we’re really going to be helping push population health into the oncology arena where we can hopefully predict and preempt this very costly and devastating disease well in advance, says Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.